 |
 |
||||||||
 |
Final Reminder - Copy Deadline: 6th October 2006Pharmaceutical and biotechnology executives refer to the Drug Delivery Report (DDR) throughout the year as the main method of independently assessing drug delivery partners.
If you want to complete a deal in 2006, then advertising in the Drug Delivery Report Autumn/Winter 2006 and on drugdeliveryreport.com is a must. Contact Kate Atherton on +44 (0) 1865 784 177 or e-mail enquiries@pharmaventures.com to find out how you can promote your company. |
||||||||
 |
 |
||||||||
 |
Market News and TrendsDuring August 2006, PharmaDeals® Agreements recorded a total of 21 deals relating to drug delivery, 13 more than the total for the previous month. Eleven of the deals involved start up companies, five were between established and start up companies and 4 were between start up companies and academic bodies; one deal was made between two global companies. A wide range of deal types were represented, including manufacture and supply agreements, asset acquisitions, marketing and distributions deals, a joint venture and business acquisition. However, the largest number, 6 in total, were licensing agreements while a further 4 were co-development and collaborative transactions. Seven deals involved neurological drug delivery devices, while other main interest areas included respiratory, research and anti-cancer. Nanotechnology, inhalable devices, a cream, injectables and a toothpaste were among the numerous innovative drug delivery devices and technologies represented among August's deals. Read more... |
||
|
|
||
Featured ArticleNanodroplet Technology Targets Drug DeliveryNanodroplet technology uses the properties of immiscible fluids to transform continuous fluid streams into highly mono-dispersed, isolated droplets with tight control of droplet size and generation rate. Using droplets, we can provide exquisite control of chemistry in picoliter or femtoliter volumes that may be merged or reacted downstream with other droplets, yielding the ability to tune the internal droplet chemistry and surface chemistry on the near-molecular level. In this article, Dr Donald Ackley, CEO of Nanotrope, Inc., discusses an application of particular interest which is the use of nanodroplets to produce designer nanoparticles for drug delivery. Read more... |
 |
||
|
|
||
 |
Company ProfilesAlkermes, Valois, Novosis, Cardinal Health |
||
|
|
||
Drug Delivery OpportunitiesView all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online.Featured Opportunity Clinical Electroporation System for Delivery of DNA Drugs Administrative Route - Intratumoural, Intramuscular Indication - DNA plasmid drug delivery Licence code - LO-0608-06 |
 |
||
|
|
||
 |
Ensure you receive your copy of the Drug Delivery Report Autumn / Winter 2006For deal makers actively assessing drug delivery technology receiving your complimentary copy is a must. The DDR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas.Apply to receive the next edition of the DDR Find out more about promoting your company |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail ddr@pharmamail.biz with the words UNSUBSCRIBE as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddr@pharmamail.biz with REMOVE as the subject.
For more details contact
Kate Atherton, Publishing Editor, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail ddr@pharmamail.biz